[{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Biodexa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Licensing Agreement","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Emtora Biosciences \/ Biodexa Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Emtora Biosciences \/ Biodexa Pharmaceuticals"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Cancer Prevention and Research Institute of Texas","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Funding","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas","highestDevelopmentStatusID":"8","companyTruncated":"Emtora Biosciences \/ Cancer Prevention and Research Institute of Texas"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Oncology","graph2":"Phase I","graph3":"Emtora Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Emtora Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Emtora Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Emtora Biosciences","sponsor":"CPRIT","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Funding","leadProduct":"Sirolimus","moa":"mTOR","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Emtora Biosciences","amount2":0.02,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Oral Capsule","sponsorNew":"Emtora Biosciences \/ CPRIT","highestDevelopmentStatusID":"10","companyTruncated":"Emtora Biosciences \/ CPRIT"}]